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Progressing an Evidence-Base Beyond Case Series
Janet Hardy, B.Sc., MBChB, M.D., FRACP,1 Meera R. Agar, M.P.C., FRACP,2,3
and David C. Currow, B.Med., M.P.H., FRACP3
Dear Editor:
We read with interest in the latest edition of this journal the
four case reports reporting dramatic responses to sub-anaes-
thetic doses of ketamine in patients with complex pain syn-
dromes poorly responsive to escalating doses of opioids.1
The management of complex pain such as this remains
challenging and at times most clinicians struggle with cases
such as these. Treatment plans in these situations tend to be
guided by physician experience and local practice and
therefore vary greatly between centres as there is often little
quality evidence to guide practice decisions.
Although it is of great interest to read of cases such as these,
there is a concern that the experience presented by the pub-
lication of case reports cannot be used as an ‘‘evidence base’’
to guide future management. Instead, it should be used as a
basis for properly blinded prospective studies.
Placebo response rates as high as 75% have been reported
in chronic pain studies.2 This may be because of patient ex-
pectation of benefit, a reflection of the extra care and attention
given to patients on trials or the fact that patients are generally
put on new treatments when their pain is at its worst and a
number will improve over time to a baseline level without
treatment. Significant placebo response rates should always
be anticipated and considered when initiating any new an-
algesic intervention.
It is well documented that uncontrolled trials may greatly
vary from subsequent point estimates in controlled studies
often with over estimates of effect3 especially if it is not a
consecutive series of cases that is presented. Conversely, case
series of people given ketamine who experience negative
outcomes are unlikely to be written or published.
Randomized trials are also needed for a true estimate
of adverse effects. The authors of this case series note few
‘‘serious effects,’’ yet report in two patients acute confusion
(presumed delirium), somnolence, and psychomimetic ef-
fects. The other two patients were proactively treated with
benzodiazepines that may have masked toxicity and equally
was associated with toxicity in themselves. In case series it is
less easy to standardize prior treatment such as opiods or
adjuvants.
High-quality randomized trials in hospice and pallia-
tive care are achievable4 to provide quality evidence to guide
our practice especially if several sites work together to con-
duct the trial.5 Palliative medicine is a specialty that is con-
tributing more and more to the care of patients with life
limiting disease. It is time we based this practice on high-
quality evidence and that can only come with high-quality
research.
References
1. Kerr C, Holahan T, Milch R; The use of ketamine in severe
cases of refractory pain syndromes in the palliative care set-
ting: a case series. J Palliat Med 2011;14:1–4.
2. McQuay H: Antidepressants and chronic pain. Br Med J
1997;314:763–764.
3. Kunz R, Oxman AD: The unpredictability paradox: review of
empirical comparisons of randomised and non-randomised
clinical trials. BMJ 1998;317:1185–1190.
4. Abernethy AP, McDonald CF, Frith PA, Clark K, Herndon
JE, Marcello J, Young IH, Bull J, Wilcock A, Booth S, Wheeler
JL, Tulsky JA, Crockett AJ, Currow DC: Effect of pallia-
tive oxygen versus room air in relief of breathlessness in
patients with refractory dyspnoea: A double-blind ran-
domized controlled trial (NCT00327873). Lancet 2010;376:
784–793.
5. Currow DC, Shelby-James TM, Agar M, Plummer J, Rowett
D, Glare P, Spruyt O, Hardy J: Planning phase III multi-site
clinical trials in palliative care: The role of consecutive cohort
audits to identify potential participant populations. J Support
Care Cancer 2010;18:1571–1578.
Address correspondence to:
David C. Currow, B.Med., M.P.H., FRACP
Discipline, Palliative, and Supportive Services
Flinders University
700 Goodwood Road
Daw Park South Australia 5041
Australia
E-mail: david.currow@flinders.edu.au
1Mater Health Services, Department of Palliative Carem Queensland, Australia.
2Department of Palliative Care, Braeside Hospital, Prairiewood, New South Wales, Australia.
3Discipline, Palliative and Supportive Services, Flinders University, Adelaide, Australia.
JOURNAL OF PALLIATIVE MEDICINE
Volume 14, Number 12, 2011
ª Mary Ann Liebert, Inc.
DOI: 10.1089/jpm.2011.0323
1283
Archived at Flinders University: dspace.flinders.edu.au
This article has been cited by:
1. Brian H. Le, Mark A. Rosenthal. 2012. Redefining the Specialist Palliative Approach: Clinical Trials, a First Year Experience.
Journal of Palliative Medicine 15:8, 846-846. [Citation] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
2. David MacKintosh, Angela Brady, Sally Carr. 2012. Ketamine: A Real-World Experience in Cancer Pain. Journal of Palliative
Medicine 15:7, 733-733. [Citation] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
Archived at Flinders University: dspace.flinders.edu.au
